Related Experiment Video
Updated: Mar 26, 2026

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
Published on: February 2, 2024
De novo Hepatocellular Carcinoma after Liver Transplantation
Sammy Saab1, Kali Zhou2, Edward K Chang2
1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract:
Liver transplantation is the definitive therapy for patients with advanced liver disease and its complications. Patients who are transplanted with a diagnosis of hepatocellular carcinoma (HCC) are at risk of recurrent cancer, and these patients are monitored on a regular basis for recurrence. In contrast, de novo HCC following liver transplantation is a very rare complication, and recipients without HCC at the time of transplantation are not screened. We describe the clinical features of de novo HCC over a decade after achieving a sustained viral response with treatment of hepatitis C and two decades after liver transplantation. Our case highlights the necessity of screening for HCC in the post-transplant patient with advanced liver disease even after viral clearance.

